Is radiation-induced ovarian ablation in breast cancer an obsolete procedure? Results of a meta-analysis

References

• ProwellTMDavidsonNEWhat is the role of ovarian ablation in the management of primary and metastatic breast cancer today?Oncologist20049550751715477635
   PubMed Web of Science ®Google Scholar
• ZhouJWuSGWangJJOvarian ablation using goserelin improves survival of premenopausal patients with stage II/III hormone receptor-positive breast cancer without chemotherapy-induced amenorrheaCancer Res Treat2015471556325187267
   PubMed Web of Science ®Google Scholar
• TaylorCWGreenSDaltonWSMulticenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup studyJ Clin Oncol19981639949999508182
   PubMed Web of Science ®Google Scholar
• BoccardoFRubagottiAPerrottaAOvarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian studyAnn Oncol1994543373428075030
   PubMed Web of Science ®Google Scholar
• JonatWKaufmannMSauerbreiWZoladex Early Breast Cancer Research Association StudyGoserelin versus cyclophosphamide, metho trexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association StudyJ Clin Oncol200220244628463512488406
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative GroupOvarian ablation in early breast cancer: overview of the randomised trialsLancet19963489036118911968898035
   PubMed Web of Science ®Google Scholar
• BeseNSIribasADiricanAOksuzDAtkovarGOberAOvarian ablation by radiation therapy: is it still an option for the ablation of ovarian function in endocrine responsive premenopausal breast cancer patients?Breast200918530430819800233
   PubMed Web of Science ®Google Scholar
• HigginsJPAltmanDGGotzschePCCochrane Bias Methods Group; Cochrane Statistical Methods GroupThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• BeggCBMazumdarMOperating characteristics of rank correlation test for publication biasBiometrics1994504108811017786990
   PubMed Web of Science ®Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• Adjuvant Breast Cancer Trials Collaborative GroupOvarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trialJ Natl Cancer Inst200799751652517405996
   PubMedGoogle Scholar
• EjlertsenBMouridsenHTJensenMBSimilar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancerJ Clin Oncol200624314956496217075113
   PubMed Web of Science ®Google Scholar
• ThurlimannBPriceKNGelberRDIs chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93Breast Cancer Res Treat2009113113714418259856
   PubMed Web of Science ®Google Scholar
• HughesLLGrayRJSolinLJEastern Cooperative Oncology GroupSouthwest Oncology GroupCancer and Leukemia Group BNorth Central Cancer Treatment GroupEfficacy of radiotherapy for ovarian ablation: results of a breast intergroup studyCancer2004101596997215329905
   PubMed Web of Science ®Google Scholar
• ThomsonCSTwelvesCJMallonEALeakeREScottish Cancer Trials Breast GroupScottish Cancer Therapy NetworkAdjuvant ovarian ablation vs. CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER statusBreast200211541942914965706
   PubMed Web of Science ®Google Scholar
• LeungSFTsaoSYTeoPMChoiPHShiuWCOvarian ablation failures by radiation: a comparison of two dose schedulesBr J Radiol1991647625375382070185
   PubMed Web of Science ®Google Scholar
• GoelSSharmaRHamiltonABeithJLHRH agonists for adjuvant therapy of early breast cancer in premenopausal womenCochrane Database Syst Rev20094CD00456219821328
   PubMed Web of Science ®Google Scholar
• BaumMHackshawAHoughtonJZIPP International Collaborators GroupAdjuvant goserelin in premenopausal patients with early breast cancer: results from the ZIPP studyEur J Cancer200642789590416545560
   PubMed Web of Science ®Google Scholar
• FisherBCostantinoJPWickerhamDLTamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 studyJ Natl Cancer Inst200597221652166216288118
   PubMed Web of Science ®Google Scholar
• CuzickJHPowlesTVeronesiUOverview of the main outcomes in breast-cancer prevention trialsLancet2003361935429630012559863
   PubMed Web of Science ®Google Scholar
• FeatherstoneCHarnettANBruntAMUltrasound localization of the ovaries for radiation-induced ovarian ablationClin Oncol (R Coll Radiol)199911639339710663329
   PubMed Web of Science ®Google Scholar
• CounsellRBainGWilliamsMVDixonAKArtificial radiation menopause: where are the ovaries?Clin Oncol (R Coll Radiol)1996842502538871004
   PubMedGoogle Scholar
• SchlemmerHPImaging for new radiotherapy techniquesCancer Imaging201010S73
   Google Scholar
• PetersNHPattersonAJHoranGGregoryDSalaEAssessment of ovarian movement on consecutive pelvic MRI examinations in patients with gynaecological malignancies: what is the planning organ-at-risk volume for radiotherapy?Breast Cancer Res Treat2009113101813714418259856
   PubMed Web of Science ®Google Scholar